The HSV-2 mutant ΔpK induces melanoma oncolysis through nonredundant death programs and associated with autophagy and pyroptosis proteins

Gene Therapy

Volumn 17, Issue 3, 2010, Pages 315-327

  Colunga, A G ^a   Laing, J M ^a   Aurelian, L ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Autophagy; Calpain; Caspases; ICP10PK; Oncolytic viruses; Pyroptosis

Indexed keywords

BECLIN 1; CALPAIN; CASPASE 3; CASPASE 7; HEAT SHOCK PROTEIN 22; INTERLEUKIN 1BETA CONVERTING ENZYME; ONCOLYTIC HERPES VIRUS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER CELL CULTURE; CANCER INHIBITION; CANCER REGRESSION; CELL DEATH; CONTROLLED STUDY; CYTOLYSIS; DRUG EFFICACY; ENZYME ACTIVATION; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN CELL; INFLAMMATION; MALE; MELANOMA; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; TUMOR XENOGRAFT; UPREGULATION; VIRUS MUTANT; VIRUS REPLICATION;

ANIMALS; APOPTOSIS; AUTOPHAGY; CALPAIN; CAPSID PROTEINS; CASPASE 3; CASPASE 7; CELL LINE, TUMOR; GENE DELETION; HERPESVIRUS 2, HUMAN; HUMANS; MELANOMA; MICE; MICE, NUDE; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; PROTEIN-SERINE-THREONINE KINASES; RIBONUCLEOTIDE REDUCTASES; SKIN NEOPLASMS; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

HUMAN HERPESVIRUS 2; MIRIDAE;

EID: 77949423196     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2009.126     Document Type: Article

References (70)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007; 57: 43-66.
2. Schatton T, Frank MH. Cancer stem cells and human malignant melanoma. Pigment Cell Melanoma Res 2008; 21: 39-55.
3. Shen Y, Nemunaitis J. Herpes simplex virus 1 (HSV-1) for cancer treatment. Cancer Gene Ther 2006; 13: 975-992.
4. Mathis JM, Stoff-Khalili MA, Curiel DT. Oncolytic adeno-viruses\selective retargeting to tumor cells. Oncogene 2005; 24: 7775-7791.
5. Ribacka C, Pesonen S, Hemminki A. Cancer, stem cells, and oncolytic viruses. Ann Med 2008; 40: 496-505.
6. Aghi M, Martuza RL. Oncolytic viral therapies\the clinical experience. Oncogene 2005; 24: 7802-7816.
7. Fu X, Tao L, Cai R, Prigge J, Zhang X. A mutant type 2 herpes simplex virus deleted for the protein kinase domain of the ICP10 gene is a potent oncolytic virus. Mol Ther 2006; 13: 882-890.
8. Kurozumi K, Hardcastle J, Thakur R, Yang M, Christoforidis G, Fulci G et al. Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy. J Natl Cancer Inst 2007; 99: 1768-1781.
9. Fulci G, Breymann L, Gianni D, Kurozomi K, Rhee SS, Yu J et al. Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proc Natl Acad Sci USA 2006; 103: 12873-12878.
10. Hu JC, Coffin RS, Davis CJ, Graham NJ, Groves N, Guest PJ et al. A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res 2006; 12: 6737-6747.
11. Kumar S, Gao L, Yeagy B, Reid T. Virus combinations and chemotherapy for the treatment of human cancers. Curr Opin Mol Ther 2008; 10: 371-379.
12. Nagano S, Perentes JY, Jain RK, Boucher Y. Cancer cell death enhances the penetration and efficacy of oncolytic herpes simplex virus in tumors. Cancer Res 2008; 68: 3795-3802.
13. Del Bello B, Moretti D, Gamberucci A, Maellaro E. Cross-talk between calpain and caspase-3/-7 in cisplatin-induced apoptosis of melanoma cells: a major role of calpain inhibition in cell death protection and p53 status. Oncogene 2007; 26: 2717-2726.
14. Vaha-Koskela MJ, Kallio JP, Jansson LC, Heikkila JE, Zakhartch-enko VA, Kallajoki MA et al. Oncolytic capacity of attenuated replicative semliki forest virus in human melanoma xenografts in severe combined immunodeficient mice. Cancer Res 2006; 66: 7185-7194.
15. Polak ME, Borthwick NJ, Gabriel FG, Johnson P, Higgins B, Hurren J et al. Mechanisms of local immunosuppression in cutaneous melanoma. Br J Cancer 2007; 96: 1879-1887.
16. Aurelian L. HSV-induced apoptosis in herpes encephalitis. Curr Top Microbiol Immunol 2005; 289: 79-111.
17. Chu CT, Zhu JH, Cao G, Signore A, Wang S, Chen J. Apoptosis inducing factor mediates caspase-independent 1-methyl-4-phe-nylpyridinium toxicity in dopaminergic cells. J Neurochem 2005; 94: 1685-1695.
18. Luo S, Rubinsztein DC. Atg5 and Bcl-2 provide novel insights into the interplay between apoptosis and autophagy. Cell Death Differ 2007; 14: 1247-1250.
19. Jain N, Sudhakar C, Swarup G. Tumor necrosis factor-alpha-induced caspase-1 gene expression. Role of p73. FEBS J 2007; 274: 4396-4407.
20. Qu X, Yu J, Bhagat G, Furuya N, Hibshoosh H, Troxel A et al. Promotion of tumorigenesis by heterozygous disruption of the Beclin 1 autophagy gene. J Clin Invest 2003; 112: 1809-1820.
21. Miracco C, Cosci E, Oliveri G, Luzi P, Pacenti L, Monciatti I et al. Protein and mRNA expression of autophagy gene Beclin 1 in human brain tumours. Int J Oncol 2007; 30: 429-436.
22. Perkins D, Pereira EF, Aurelian L. The herpes simplex virus type 2 R1 protein kinase (ICP10 PK) functions as a dominant regulator of apoptosis in hippocampal neurons involving activation of the ERK survival pathway and upregulation of the antiapoptotic protein Bag-1. J Virol 2003; 77: 1292-1305.
23. Laing JM, Gober MD, Golembewski EK, Thompson SM, Gyure KA, Yarowsky PJ et al. Intranasal administration of the growth-compromised HSV-2 vector DeltaRR prevents kainate-induced seizures and neuronal loss in rats and mice. [published erratum appears in Mol Ther 2007; 15: 1734]. Mol Ther 2006; 13: 870-881.
24. Gober MD, Laing JM, Thompson SM, Aurelian L. The growth compromised HSV-2 mutant DeltaRR prevents kainic acid-induced apoptosis and loss of function in organotypic hippo-campal cultures. Brain Res 2006; 1119: 26-39.
25. Golembewski EK, Wales SQ, Aurelian L, Yarowsky PJ. The HSV-2 protein ICP10PK prevents neuronal apoptosis and loss of function in an in vivo model of neurodegeneration associated with glutamate excitotoxicity. Exp Neurol 2007; 203: 381-393.
26. Wales SQ, Li B, Laing JM, Aurelian L. The herpes simplex virus type 2 gene ICP10PK protects from apoptosis caused by nerve growth factor deprivation through inhibition of caspase-3 activation and XIAP up-regulation. J Neurochem 2007; 103: 365-379.
27. Wales SQ, Laing JM, Chen L, Aurelian L. ICP10PK inhibits calpain-dependent release of apoptosis-inducing factor and programmed cell death in response to the toxin MPP+. Gene Therapy 2008; 15: 1397-1409.
28. Gyotoku T, Ono F, Aurelian L. Development of HSV-specific CD4+ Th1 responses and CD8+ cytotoxic T lymphocytes with antiviral activity by vaccination with the HSV-2 mutant ICP10DeltaPK. Vaccine 2002; 20: 2796-2807.
29. Minkis K, Kavanagh DG, Alter G, Bogunovic D, O'Neill D, Adams S et al. Type 2 bias of T cells expanded from the blood of melanoma patients switched to type 1 by IL-12p70 mRNA-transfected dendritic cells. Cancer Res 2008; 68: 9441-9450.
30. Casanova G, Cancela R, Alonzo L, Benuto R, Magana Mdel C, Hurley DR et al. A double-blind study of the efficacy and safety of the ICP10deltaPK vaccine against recurrent genital HSV-2 infections. Cutis 2002; 70: 235-239.
31. Aurelian L. Herpes simplex virus type 2 vaccines: new ground for optimism? Clin Diagn Lab Immunol 2004; 11: 437-445.
32. Li B, Smith CC, Laing JM, Gober MD, Liu L, Aurelian L. Overload of the heat-shock protein H11/HspB8 triggers melanoma cell apoptosis through activation of transforming growth factor-beta-activated kinase 1. Oncogene 2007; 26: 3521-3531.
33. Smith CC, Peng T, Kulka M, Aurelian L. The PK domain of the large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10) is required for immediate-early gene expression and virus growth. J Virol 1998; 72: 9131-9141.
34. Smith CC, Nelson J, Aurelian L, Gober M, Goswami BB. Ras-GAP binding and phosphorylation by herpes simplex virus type 2 RR1 PK (ICP10) and activation of the Ras/MEK/MAPK mitogenic pathway are required for timely onset of virus growth. J Virol 2000; 74: 10417-10429.
35. Omholt K, Platz A, Kanter L, Ringborg U, Hansson J. NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin Cancer Res 2003; 9: 6483-6488.
36. Manohar M, Orrison B, Peden K, Lewis Jr AM. Assessing the tumorigenic phenotype of VERO cells in adult and newborn nude mice. Biologicals 2008; 36: 65-72.
37. Wymer JP, Chung TD, Chang YN, Hayward GS, Aurelian L. Identification of immediate-early-type cis-response elements in the promoter for the ribonucleotide reductase large subunit from herpes simplex virus type 2. J Virol 1989; 63: 2773-2784.
38. Knipe DM, Fields BN, Howley PM, Griffin D, Lamb R, Martin MA. Fields' Virology. Wolters Kluwer Health/Lippincott Williams & Wilkins: Philadelphia, PA c2007 2007, pp 86.
39. Sheridan JF, Beck M, Smith CC, Aurelian L. Reactivation of herpes simplex virus is associated with production of a low molecular weight factor that inhibits lymphokine activity in vitro. J Immunol 1987; 138: 1234-1239.
40. Walsh JG, Cullen SP, Sheridan C, Luthi AU, Gerner C, Martin SJ. Executioner caspase-3 and caspase-7 are functionally distinct proteases. Proc Natl Acad Sci USA 2008; 105: 12815-12819.
41. Goll DE, Thompson VF, Li H, Wei W, Cong J. The calpain system. Physiol Rev 2003; 83: 731-801.
42. Bizat N, Hermel JM, Humbert S, Jacquard C, Creminon C, Escartin C et al. In vivo calpain/caspase cross-talk during 3-nitropropionic acid-induced striatal degeneration: implication of a calpain-mediated cleavage of active caspase-3. J Biol Chem 2003; 278: 43245-43253.
43. Neumar RW, Xu YA, Gada H, Guttmann RP, Siman R. Cross-talk between calpain and caspase proteolytic systems during neuronal apoptosis. J Biol Chem 2003; 278: 14162-14167.
44. Fernandes-Alnemri T, Wu J, Yu JW, Datta P, Miller B, Jankowski W et al. The pyroptosome: a supramolecular assembly of ASC dimers mediating inflammatory cell death via caspase-1 activation. Cell Death Differ 2007; 14: 1590-1604.
45. Yu HB, Finlay BB. The caspase-1 inflammasome: a pilot of innate immune responses. Cell Host Microbe 2008; 4: 198-208.
46. Laing JM, Aurelian L. DeltaRR vaccination protects from KA-induced seizures and neuronal loss through ICP10PK-mediated modulation of the neuronal-microglial axis. Genet Vaccines Ther 2008; 6: 1.
47. Villeneuve J, Tremblay P, Vallieres L. Tumor necrosis factor reduces brain tumor growth by enhancing macrophage recruitment and microcyst formation. Cancer Res 2005; 65: 3928-3936.
48. Aghi M, Visted T, Depinho RA, Chiocca EA. Oncolytic herpes virus with defective ICP6 specifically replicates in quiescent cells with homozygous genetic mutations in p16. Oncogene 2008; 27: 4249-4254.
49. Yun CO. Overcoming the extracellular matrix barrier to improve intratumoral spread and therapeutic potential of oncolytic virotherapy. Curr Opin Mol Ther 2008; 10: 356-361.
50. MacKie RM, Stewart B, Brown SM. Intralesional injection of herpes simplex virus 1716 in metastatic melanoma. Lancet 2001; 357: 525-526.
51. Smith CC, Luo JH, Hunter JC, Ordonez JV, Aurelian L. The transmembrane domain of the large subunit of HSV-2 ribonu-cleotide reductase (ICP10) is required for protein kinase activity and transformation-related signaling pathways that result in ras activation. Virology 1994; 200: 598-612.
52. Luo JH, Aurelian L. The transmembrane helical segment but not the invariant lysine is required for the kinase activity of the large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10). J Biol Chem 1992; 267: 9645-9653.
53. Smith CC, Aurelian L. The large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10) is associated with the virion tegument and has PK activity. Virology 1997; 234: 235-242.
54. Gober MD, Wales SQ, Hunter JC, Sharma BK, Aurelian L. Stress up-regulates neuronal expression of the herpes simplex virus type 2 large subunit of ribonucleotide reductase (R1; ICP10) by activating activator protein 1. J Neurovirol 2005; 11: 329-336.
55. Royuela M, Rodriguez-Berriguete G, Fraile B, Paniagua R. TNF-alpha/IL-1/NF-kappaB transduction pathway in human cancer prostate. Histol Histopathol 2008; 23: 1279-1290.
56. Fu X, Tao L, Zhang X. An oncolytic virus derived from type 2 herpes simplex virus has potent therapeutic effect against metastatic ovarian cancer. Cancer Gene Ther 2007; 14: 480-487.
57. Fu X, Tao L, Zhang X. An HSV-2-based oncolytic virus deleted in the PK domain of the ICP10 gene is a potent inducer of apoptotic death in tumor cells. Gene Therapy 2007; 14: 1218-1225.
58. Lamkanfi M, Kanneganti TD, Van Damme P, Vanden Berghe T, Vanoverberghe I, Vandekerckhove J et al. Targeted peptide-centric proteomics reveals caspase-7 as a substrate of the caspase-1 inflammasomes. Mol Cell Proteomics 2008; 7: 2350-2363.
59. Sung YH, Lee JS, Park SH, Koo J, Lee GM. Influence of co-down-regulation of caspase-3 and caspase-7 by siRNAs on sodium butyrate-induced apoptotic cell death of Chinese hamster ovary cells producing thrombopoietin. Metab Eng 2007; 9: 452-464.
60. Choi WS, Lee EH, Chung CW, Jung YK, Jin BK, Kim SU et al. Cleavage of Bax is mediated by caspase-dependent or independent calpain activation in dopaminergic neuronal cells: protective role of Bcl-2. J Neurochem 2001; 77: 1531-1541.
61. Han BS, Hong HS, Choi WS, Markelonis GJ, Oh TH, Oh YJ. Caspase-dependent and-independent cell death pathways in primary cultures of mesencephalic dopaminergic neurons after neurotoxin treatment. J Neurosci 2003; 23: 5069-5078.
62. Shacka JJ, Roth KA, Zhang J. The autophagy-lysosomal degradation pathway: role in neurodegenerative disease and therapy. Front Biosci 2008; 13: 718-736.
63. Gao G, Dou QP. N-terminal cleavage of bax by calpain generates a potent proapoptotic 18-kDa fragment that promotes bcl-2-independent cytochrome C release and apoptotic cell death. J Cell Biochem 2000; 80: 53-72.
64. Takano J, Tomioka M, Tsubuki S, Higuchi M, Iwata N, Itohara S et al. Calpain mediates excitotoxic DNA fragmentation via mitochondrial pathways in adult brains: evidence from calpas-tatin mutant mice. J Biol Chem 2005; 280: 16175-16184.
65. Cao G, Xing J, Xiao X, Liou AK, Gao Y, Yin XM et al. Critical role of calpain I in mitochondrial release of apoptosis-inducing factor in ischemic neuronal injury. J Neurosci 2007; 27: 9278-9293.
66. Sanfilippo CM, Blaho JA. ICP0 gene expression is a herpes simplex virus type 1 apoptotic trigger. J Virol 2006; 80: 6810-6821.
67. Mahller YY, Sakthivel B, Baird WH, Aronow BJ, Hsu YH, Cripe TP et al. Molecular analysis of human cancer cells infected by an oncolytic HSV-1 reveals multiple upregulated cellular genes and a role for SOCS1 in virus replication. Cancer Gene Ther 2008; 15: 733-741.
68. Huszthy PC, Goplen D, Thorsen F, Immervoll H, Wang J, Gutermann A et al. Oncolytic herpes simplex virus type-1 therapy in a highly infiltrative animal model of human glioblastoma. Clin Cancer Res 2008; 14: 1571-1580.
69. White E. Autophagic cell death unraveled: pharmacological inhibition of apoptosis and autophagy enables necrosis. Autophagy 2008; 4: 399-401.
70. Levine B, Sinha S, Kroemer G. Bcl-2 family members: dual regulators of apoptosis and autophagy. Autophagy 2008; 4: 600-606.